Ensysce Biosciences reports Q3 net loss

Ensysce Biosciences

14/11/2025 21:25

Overview

Ensysce reports Q3 net loss of $3.7 mln, driven by increased R&D expenses

Company initiates Phase 3 study of PF614, marking a major milestone

Ensysce completes $4 mln preferred stock financing to support development

Result Drivers

Cash and cash equivalents were $1.7 million as of September 30, 2025, compared to $3.5 million as of December 31, 2024

R&D expenses were $3.0 million for the third quarter of 2025 compared to $1.7 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.29
Q3 Net Income
-$3.7 mln


Analyst Coverage

Wall Street's median 12-month price target for Ensysce Biosciences Inc is $26.23, about 92.1% above its November 13 closing price of $2.07

Press Release: ID:nACS5KjHQa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)